Assisted lead counsel in representing Biotest AG (Biotest), a German publicly traded biotechnology company, in signing a global License, Development and Commercialization Agreement with Abbott Laboratories for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million, and upon completion of certain milestones, additional payments totaling $395 million, plus royalties.

Experience Center

Match our Experience to Your Needs

Experience Highlights

Copyright infringement litigation defense for one of the world's leading music companies
Represented one of the world's leading music companies in copyright infringement litigation. Summary judgment was granted in favor of our more
Asbestos property damage litigation for a national building and construction products manufacturer
Served as defense counsel for a national building and construction products manufacturer in landmark asbestos property damage litigation. more
Dispute mitigation counsel to a major oil and gas company
Represent a major oil and gas exploration and production services company in an early dispute mitigation regarding an more
Finance transaction for a leading European financial services company
Represented a leading European financial services company in connection with a €140 million sale and lease back connected to a Swedish power more